vs
Side-by-side financial comparison of Clear Channel Outdoor Holdings, Inc. (CCO) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Clear Channel Outdoor Holdings, Inc. is the larger business by last-quarter revenue ($461.5M vs $346.4M, roughly 1.3× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 28.1% vs 1.7%, a 26.4% gap on every dollar of revenue. On growth, Clear Channel Outdoor Holdings, Inc. posted the faster year-over-year revenue change (8.2% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $30.3M). Over the past eight quarters, Clear Channel Outdoor Holdings, Inc.'s revenue compounded faster (18.8% CAGR vs 1.5%).
Clear Channel Outdoor Holdings, Inc. is a multinational corporation focused on outdoor advertising. The company is based in San Antonio, Texas.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CCO vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $461.5M | $346.4M |
| Net Profit | $8.0M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | 23.3% | 36.1% |
| Net Margin | 1.7% | 28.1% |
| Revenue YoY | 8.2% | 4.8% |
| Net Profit YoY | 144.8% | — |
| EPS (diluted) | $0.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $346.4M | ||
| Q4 25 | $461.5M | $339.0M | ||
| Q3 25 | $405.6M | $327.3M | ||
| Q2 25 | $402.8M | $321.4M | ||
| Q1 25 | $334.2M | $330.6M | ||
| Q4 24 | $426.7M | $348.5M | ||
| Q3 24 | $375.2M | $345.5M | ||
| Q2 24 | $376.5M | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $8.0M | $44.7M | ||
| Q3 25 | $-60.1M | $38.7M | ||
| Q2 25 | $9.5M | $34.0M | ||
| Q1 25 | $62.5M | $58.0M | ||
| Q4 24 | $-17.9M | $37.5M | ||
| Q3 24 | $-32.5M | $33.8M | ||
| Q2 24 | $-39.2M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 23.3% | 19.9% | ||
| Q3 25 | 19.9% | 17.9% | ||
| Q2 25 | 19.2% | 16.8% | ||
| Q1 25 | 13.5% | 21.6% | ||
| Q4 24 | 23.5% | 16.9% | ||
| Q3 24 | 17.8% | 15.0% | ||
| Q2 24 | 18.2% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | 1.7% | 13.2% | ||
| Q3 25 | -14.8% | 11.8% | ||
| Q2 25 | 2.4% | 10.6% | ||
| Q1 25 | 18.7% | 17.5% | ||
| Q4 24 | -4.2% | 10.8% | ||
| Q3 24 | -8.7% | 9.8% | ||
| Q2 24 | -10.4% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | $0.01 | $0.95 | ||
| Q3 25 | $-0.12 | $0.81 | ||
| Q2 25 | $0.02 | $0.70 | ||
| Q1 25 | $0.13 | $1.17 | ||
| Q4 24 | $-0.03 | $0.74 | ||
| Q3 24 | $-0.07 | $0.66 | ||
| Q2 24 | $-0.08 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $190.0M | $245.4M |
| Total DebtLower is stronger | $5.1B | $1.2B |
| Stockholders' EquityBook value | $-3.4B | $796.3M |
| Total Assets | $3.8B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | $190.0M | $363.4M | ||
| Q3 25 | $155.0M | $296.4M | ||
| Q2 25 | $138.6M | $292.9M | ||
| Q1 25 | $395.8M | $306.8M | ||
| Q4 24 | $109.7M | $320.8M | ||
| Q3 24 | $201.1M | $299.3M | ||
| Q2 24 | $189.3M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.1B | $1.2B | ||
| Q3 25 | $5.1B | $1.2B | ||
| Q2 25 | $5.1B | $1.2B | ||
| Q1 25 | $5.3B | $1.2B | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $5.7B | — | ||
| Q2 24 | $5.7B | — |
| Q1 26 | — | $796.3M | ||
| Q4 25 | $-3.4B | $911.5M | ||
| Q3 25 | $-3.5B | $849.2M | ||
| Q2 25 | $-3.4B | $882.3M | ||
| Q1 25 | $-3.4B | $820.8M | ||
| Q4 24 | $-3.6B | $906.9M | ||
| Q3 24 | $-3.6B | $878.9M | ||
| Q2 24 | $-3.6B | $905.4M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $3.8B | $2.5B | ||
| Q3 25 | $3.8B | $2.4B | ||
| Q2 25 | $3.8B | $2.5B | ||
| Q1 25 | $4.0B | $2.5B | ||
| Q4 24 | $4.8B | $2.5B | ||
| Q3 24 | $4.6B | $2.5B | ||
| Q2 24 | $4.5B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $56.3M | $293.2M |
| Free Cash FlowOCF − Capex | $30.3M | $209.9M |
| FCF MarginFCF / Revenue | 6.6% | 60.6% |
| Capex IntensityCapex / Revenue | 5.6% | 9.5% |
| Cash ConversionOCF / Net Profit | 7.04× | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $32.0M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $56.3M | $93.6M | ||
| Q3 25 | $56.2M | $111.3M | ||
| Q2 25 | $-12.6M | $17.4M | ||
| Q1 25 | $14.9M | $116.6M | ||
| Q4 24 | $29.3M | $43.8M | ||
| Q3 24 | $54.5M | $48.8M | ||
| Q2 24 | $30.8M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | $30.3M | $87.2M | ||
| Q3 25 | $41.4M | $106.3M | ||
| Q2 25 | $-29.2M | $13.6M | ||
| Q1 25 | $-10.6M | $100.9M | ||
| Q4 24 | $-27.8M | $35.2M | ||
| Q3 24 | $21.0M | $39.4M | ||
| Q2 24 | $5.2M | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | 6.6% | 25.7% | ||
| Q3 25 | 10.2% | 32.5% | ||
| Q2 25 | -7.2% | 4.2% | ||
| Q1 25 | -3.2% | 30.5% | ||
| Q4 24 | -6.5% | 10.1% | ||
| Q3 24 | 5.6% | 11.4% | ||
| Q2 24 | 1.4% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 5.6% | 1.9% | ||
| Q3 25 | 3.7% | 1.5% | ||
| Q2 25 | 4.1% | 1.2% | ||
| Q1 25 | 7.6% | 4.7% | ||
| Q4 24 | 13.4% | 2.5% | ||
| Q3 24 | 8.9% | 2.7% | ||
| Q2 24 | 6.8% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 7.04× | 2.09× | ||
| Q3 25 | — | 2.88× | ||
| Q2 25 | -1.32× | 0.51× | ||
| Q1 25 | 0.24× | 2.01× | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | 1.44× | ||
| Q2 24 | — | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCO
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
